A divided Congress will mark the next two years of U.S. government, with the Democrats controlling the House of Representatives and the Republicans likely increasing their hold on the Senate. That could portend increased gridlock on major initiatives and the likelihood that Congress won't do much in the way of making new policy. In other words, the status quo will solidify. For many in the biopharma and med-tech sector, that's good news, as it could improve investor sentiment and lessen concerns about congressional pressure on drug pricing.